Unichem实验室计划通过将海湾制药公司纳入Unichem制药公司(美国)来巩固其美国非专利药品业务。 Unichem Laboratories plans to consolidate its US generics business by integrating Bayshore Pharmaceuticals into Unichem Pharmaceuticals (USA).

印度一家制药公司Unichem Laboratories计划将其美国非专利药品业务并入Unichem制药公司(美国),以此巩固其美国非专利药品业务。 Unichem Laboratories, an Indian pharmaceutical firm, plans to consolidate its US generics business by integrating Bayshore Pharmaceuticals LLC into Unichem Pharmaceuticals (USA) Inc. 这一战略行动旨在统一伊普卡集团的所有美国行动。 This strategic move aims to unify all of Ipca Group's US operations. 董事会将于2024年9月30日讨论此事。 The board will discuss this on September 30, 2024. 宣布之后,Unichem的股份波动不定,反映了最近的下滑和先前的增加。 Following the announcement, Unichem's shares fluctuated, reflecting a recent downturn and a prior increase. 该公司报告,25财政年度第1季度净利润为9.26卢比。 The company reported a net profit of Rs 9.26 crore for Q1 FY25.